Cargando…

Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series

Merkel cell carcinoma (MCC) is a rare but clinically aggressive cancer with a high mortality rate. In recent years, antibodies blocking the interactions among PD-1 and its ligands have generated durable tumor regressions in patients with advanced MCC. However, there is a paucity of data regarding ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	LoPiccolo, Jaclyn, Schollenberger, Megan D., Dakhil, Sumia, Rosner, Samuel, Ali, Osama, Sharfman, William H., Silk, Ann W., Bhatia, Shailender, Lipson, Evan J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615256/ https://www.ncbi.nlm.nih.gov/pubmed/31287031 http://dx.doi.org/10.1186/s40425-019-0661-6

Ejemplares similares

Immunotherapy for Merkel cell carcinoma: a turning point in patient care
por: Chan, Isaac S., et al.
Publicado: (2018)

Complete resolution of PD-1 refractory, locoregionally advanced Merkel cell carcinoma with talimogene laherparepvec
por: Singh, Neha, et al.
Publicado: (2023)

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
por: Lipson, Evan J., et al.
Publicado: (2017)

Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy
por: Miller, Natalie J., et al.
Publicado: (2018)

Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study
por: Bhatia, Shailender, et al.
Publicado: (2022)

Rescue of Immunotherapy-Refractory Metastatic Merkel Cell Carcinoma With Conventionally Fractionated Radiotherapy and Concurrent Pembrolizumab
por: Bloom, Brooke C., et al.
Publicado: (2019)

Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis
por: Jain, Animesh, et al.
Publicado: (2017)

Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma
por: Tachiki, Lisa May Ling, et al.
Publicado: (2023)

Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma
por: Rosner, Samuel, et al.
Publicado: (2020)

How we treat Merkel cell carcinoma: within and beyond current guidelines
por: Park, Song Y, et al.
Publicado: (2021)

Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
por: Nghiem, Paul, et al.
Publicado: (2021)

Clinical Benefit from Tyrosine Kinase Inhibitors in Metastatic Merkel Cell Carcinoma: A Case Series of 5 Patients
por: Tarabadkar, Erica S., et al.
Publicado: (2018)

Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab
por: Giraldo, Nicolas A., et al.
Publicado: (2018)

Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma
por: Iyer, Jayasri G., et al.
Publicado: (2016)

Management and Prognosis of Cardiac Metastatic Merkel Cell Carcinoma: A Case–Control Study and Literature Review
por: Akaike, Tomoko, et al.
Publicado: (2022)

Postoperative, Single-Fraction Radiation Therapy in Merkel Cell Carcinoma of the Head and Neck
por: Cook, Maclean M., et al.
Publicado: (2020)

Utility of Serial Donor-derived Cell-free DNA Measurements for Detecting Allograft Rejection in a Kidney Transplant Recipient After PD-1 Checkpoint Inhibitor Administration
por: Lakhani, Laila, et al.
Publicado: (2021)

Single-fraction radiation therapy in patients with metastatic Merkel cell carcinoma
por: Iyer, Jayasri G, et al.
Publicado: (2015)

Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG
por: Glutsch, Valerie, et al.
Publicado: (2022)

Systemic immune suppression as a stage-independent predictor of diminished Merkel cell carcinoma-specific survival
por: Paulson, Kelly G., et al.
Publicado: (2012)

Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
por: Kaufman, Howard L., et al.
Publicado: (2018)

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
por: Glutsch, Valerie, et al.
Publicado: (2021)

Predictors of immunotherapy benefit in Merkel cell carcinoma
por: Kacew, Alec J., et al.
Publicado: (2020)

Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
por: D'Angelo, Sandra P, et al.
Publicado: (2020)

From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real‐world setting
por: Rowe, Steven P., et al.
Publicado: (2018)

Patterns of distant metastases in 215 Merkel cell carcinoma patients: Implications for prognosis and surveillance
por: Lewis, Christopher W., et al.
Publicado: (2019)

Merkel Cell Polyomavirus and Merkel Cell Carcinoma
por: Pietropaolo, Valeria, et al.
Publicado: (2020)

DETECTing Merkel Cell Polyomavirus in Merkel Tumors
por: Arora, Reety, et al.
Publicado: (2020)

Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies
por: Lipson, Evan J.
Publicado: (2013)

Utilizing Electronic Health Records (EHR) and Tumor Panel Sequencing to Demystify Prognosis of Cancer of Unknown Primary (CUP) patients
por: Moon, Intae, et al.
Publicado: (2023)

Merkel Cell Polyomavirus and Merkel Cell Carcinoma, France
por: Foulongne, Vincent, et al.
Publicado: (2008)

Merkel cell polyomavirus and cutaneous Merkel cell carcinoma
por: Minutilli, Ettore, et al.
Publicado: (2016)

Merkel cell polyomavirus and associated Merkel cell carcinoma
por: Yang, June F., et al.
Publicado: (2021)

Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma
por: D’Angelo, Sandra P., et al.
Publicado: (2019)

Merkel Cell Polyomavirus Strains in Patients with Merkel Cell Carcinoma
por: Touzé, Antoine, et al.
Publicado: (2009)

Merkel cell polyomavirus in Merkel cell carcinoma of Italian patients
por: Paolini, Francesca, et al.
Publicado: (2011)

Prokineticins and Merkel cell polyomavirus infection in Merkel cell carcinoma
por: Lauttia, S, et al.
Publicado: (2014)

Epidemiology of Merkel Cell Polyomavirus Infection and Merkel Cell Carcinoma
por: Silling, Steffi, et al.
Publicado: (2022)

Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma
por: Spassova, Ivelina, et al.
Publicado: (2022)

Response to Anti-PD-1 Therapy in Metastatic Merkel Cell Carcinoma Metastatic to the Heart and Pancreas
por: Mantripragada, Kalyan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_iaiev1d3gonbod5aman3pb70gn